Andrew Allen, Gritstone bio CEO (Gritstone via website)
July 22, 2022 11:08 AM EDTUpdated 04:01 PM
Financing

Up­dat­ed: Grit­stone goes the cred­it fa­cil­i­ty route, se­cur­ing $80M to keep clin­i­cal ef­forts run­ning

Paul Schloesser

Associate Editor

A Cal­i­for­nia de­vel­op­er is fol­low­ing up on one of the hottest trends in biotech, tak­ing out a loan to ex­tend its op­er­at­ing run­way while the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times